FATTY ACID AMIDE HYDROLASE (FAAH) CLEAVABLE PRODRUGS OF BRAIN TARGETING ACTIVES AND COMBINATION WITH PERIPHERALLY RESTRICTED FAAH INHIBITORS

Provided herein are fatty acid amide (FAAH) cleavable prodrugs of compounds that modulate a target in the brain including sphingosine- 1 -phosphate receptor (S1P1), lysophosphatidic acid receptor 1 (LPA1), G-protein coupled receptor 120 (GPR120), prostacyclin (PGI2), and transthyretin (TTR). Pharmac...

Full description

Saved in:
Bibliographic Details
Main Authors STEARNS, Brian Andrew, HARRIS, Jason Randall, BACCEI, Jill Melissa
Format Patent
LanguageEnglish
French
Published 10.11.2022
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Provided herein are fatty acid amide (FAAH) cleavable prodrugs of compounds that modulate a target in the brain including sphingosine- 1 -phosphate receptor (S1P1), lysophosphatidic acid receptor 1 (LPA1), G-protein coupled receptor 120 (GPR120), prostacyclin (PGI2), and transthyretin (TTR). Pharmaceutical compositions comprising these prodrugs, including in combination with a peripherally restricted FAAH inhibitor, and at least one pharmaceutically acceptable excipient, are also provided, and the use of these compounds and compositions in the treatment of CNS diseases or disorders. La présente invention concerne des promédicaments clivables d'amide d'acide gras (FAAH) de composés qui modulent une cible dans le cerveau comprenant le récepteur de sphingosine-1-phosphate (S1P1), le récepteur 1 de l'acide lysophosphatidique (LPA1), le récepteur 120 couplé à la protéine G (GPR120), la prostacycline (PGI2) et la transthyrétine (TTR). L'invention concerne également des compositions pharmaceutiques comprenant ces promédicaments, notamment en combinaison avec un inhibiteur de FAAH à restriction périphérique, et au moins un excipient pharmaceutiquement acceptable, ainsi que l'utilisation de ces composés et compositions dans le traitement de maladies ou de troubles du SNC.
Bibliography:Application Number: WO2022US28164